1
TÍTULO: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer
AUTORES: Schmid, P; Ferreira, M; Dubey, S; Zaiss, M; Harper Wynne, C; Makris, A; Brown, V; Kristeleit, H; Patel, G; Perello, A; Jones, A; Mithal, N; Ruiz, I; Kummel, S; Brunt, AM; Guerra, JA; Gonzalez G Cao; Saura, C; Mousa, K; Sarker, SJ; Coetzee, C; Swann, R; Cortes, J; ...Mais
PUBLICAÇÃO: 2016, FONTE: 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 76, NÚMERO: 4 Supplement
INDEXADO EM: WOS CrossRef